multiple myeloma
Conditions
Interventions
1:lenalidomide lenalidomide combined with infusion of anti-BCMA CAR-T and anti-CD19 CAR-T therapy
Sponsors
the Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with multiple myeloma have no effective treatment options (such as autologous or allogeneic stem cell transplantation) and have limited prognosis with existing therapies ( 12 weeks; [3] Multiple myeloma diagnosed by physical examination, pathological examination, laboratory examination and imaging; [4] Patients with multiple myeloma chemotherapy failure; [5] Patients with multiple myeloma recurrence; [6] ALT, AST 50%; [9] Failure of autologous stem cell and allogeneic stem cell transplantation; [10] Not suitable for stem cell transplantation conditions or for abandoning transplantation due to conditional restrictions; [11] Blood can be taken intravenously without other contraindications for leukapheresis; [12] Can understand and voluntarily sign written informed consent.
Exclusion criteria
Exclusion criteria: [1] pregnant or lactating women, or women with a pregnancy plan within six months; [2] infectious diseases (such as HIV, active tuberculosis, etc.); [3] Active hepatitis B or C infection; [4] Feasibility assessment screening demonstrates that transfection of targeted lymphocytes is < 10% or insufficiently amplified by CD3/CD28 co-stimulation (< 5 fold); [5] Vital signs are not normal and cannot be matched with the examiner; [6] Those who have mental or mental illnesses that cannot be combined with treatment and efficacy evaluation; [7] Highly allergic or have a history of severe allergies, especially those who are allergic to IL-2; [8] Systemic infections or localized serious infections require anti-infective treatment of subjects; [9] Combine dysfunction of important organs such as heart, lung, brain and kidney; [10] Subjects with severe autoimmune diseases; [11] The doctor believes that there are other reasons that cannot be included in the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactLi Zhenyu
Department of Hematology, the Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed